Midostaurin

6 trials 3 recruiting LOncology Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

6 Sponsors

15 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 3 Phase I/II: 1

Oversight events:

3 serious breaches 1 corrective measure across 3 trials

View oversight register →

Indications tested

Acute myeloid leukaemia 2 Myelodysplastic syndrome 1

Sponsors using this IMP

Fondazione Gimema Franco Mandelli Onlus 1 Haemato Oncology Foundation For Adults Netherlands 1 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 1 Medical University Of Lodz 1 Novartis Pharma AG 1 Technische Universitat Dresden 1

All trials

6 total

MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leu… Recruiting

2023-503394-37-00 Phase III 1 country Medical University Of Lodz
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 Phase I/II 1 country Technische Universitaet Dresden
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Phase II 11 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit… Ended

2023-503829-18-00 Phase II 2 countries Haemato Oncology Foundation For Adults Netherlands
A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended

2023-509834-20-00 Phase II 6 countries Novartis Pharma AG

Showing 1–6 of 6 trials

← All drugs A–Z